INVOKAMET XR Drug Patent Profile

When do Invokamet Xr patents expire, and what generic alternatives are available?

Invokamet Xr is a drug marketed by Janssen Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty patent family members in forty-five countries.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Invokamet Xr

Invokamet Xr was eligible for patent challenges on March 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 26, 2029. This may change due to patent challenges or generic licensing.

There have been twenty-seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for INVOKAMET XR

International Patents:	220
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Drug Prices:	Drug price information for INVOKAMET XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVOKAMET XR
DailyMed Link:	INVOKAMET XR at DailyMed

See drug prices for INVOKAMET XR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INVOKAMET XR

Constraining patent/regulatory exclusivity:

7,943,582*PED

NDA:

205879

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for INVOKAMET XR

Drug Class	Biguanide Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	P-Glycoprotein Inhibitors Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for INVOKAMET XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVOKAMET XR	Extended-release Tablets	canagliflozin; metformin hydrochloride	50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg	205879	1	2018-11-21

US Patents and Regulatory Information for INVOKAMET XR

INVOKAMET XR is protected by three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 7,943,582.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No	7,943,788*PED				Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016		RX	Yes	No	7,943,582*PED				Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016		RX	Yes	No	7,943,788*PED				Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No

Expired US Patents for INVOKAMET XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-004	Sep 20, 2016	8,785,403
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016	8,785,403
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016	6,723,340
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016	6,723,340

International Patents for INVOKAMET XR

When does loss-of-exclusivity occur for INVOKAMET XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Guatemala

Honduras

Israel

Japan

Malaysia

Mexico

Montenegro

New Zealand

Nicaragua

Norway

Panama

Peru

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVOKAMET XR around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2456640
Taiwan	201038588	Novel compounds
Australia	2007329895
Brazil	PI0606806	compostos indólicos, suas composições e seus usos

Supplementary Protection Certificates for INVOKAMET XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1651658	CR 2014 00024	Denmark		PRODUCT NAME: CANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001-008 20131119
1651658	1490027-8	Sweden		PERIOD OF VALIDITY (FROM - UNTIL): 20240731 - 20281118
1651658	2014/029	Ireland		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
1651658	29/2014	Austria		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884 20131115

Market Dynamics and Financial Trajectory for INVOKAMET XR

Last updated: February 20, 2026

What is the current market position of INVOKAMET XR?

INVOKAMET XR, developed by Merck & Co., combines empagliflozin, an SGLT2 inhibitor, with metformin hydrochloride. Approved by the FDA in 2017, it addresses type 2 diabetes mellitus and has gained market share driven by the increasing prevalence of diabetes globally.

The drug is positioned within the combined oral antidiabetic therapy segment, competing with similar fixed-dose combinations such as Janumet XR (Eli Lilly), Glucovance, and Jardiance combinations.

In 2022, the total U.S. diabetes drug market was valued at approximately $16 billion, with INVOKAMET XR accounting for an estimated 3% share, reflecting sales of around $480 million (IQVIA, 2023). Its market penetration remains steady, owing to patient and doctor preference for combination products that improve adherence.

What are the drivers influencing demand for INVOKAMET XR?

Increase in Diabetes Prevalence

Global prevalence of type 2 diabetes exceeds 400 million and is projected to reach 700 million by 2045 (IDF, 2022). This demographic growth alone supports sustained demand for combination therapies like INVOKAMET XR.

Guideline Recommendations

The American Diabetes Association endorses SGLT2 inhibitors for patients with high cardiovascular risk, expanding their use beyond glucose control to cardiovascular and renal benefits. As empagliflozin demonstrated reduced cardiovascular death in EMPA-REG OUTCOME trial, demand for products including empagliflozin rises (Zinman et al., 2015).

Regulatory Considerations

INVOKAMET XR's label includes indications for weight and blood pressure benefits, aligning with treatment shifts toward multifactorial management of comorbidities, thus broadening its therapeutic appeal.

Competitive Landscape

The entry of biosimilars and other combination drugs pressures pricing and market share. Yet, INVOKAMET XR's branded status, clinical data, and physician familiarity sustain its position.

How are pricing and reimbursement influencing financial performance?

Pricing Strategy

Average wholesale price (AWP) for INVOKAMET XR is approximately $550 for a 30-day supply, with actual net prices varying based on discounts and insurance contracts (GoodRx, 2023). Price increases are limited due to competitive pressures and policy constraints.

Reimbursement Landscape

Insurance coverage is favorable, with most payers including INVOKAMET XR in formulary tiers, often requiring prior authorization. Medicare Part D plans primarily cover the drug, influencing sales in the U.S.

Impact on Revenue

Reimbursement policies, combined with increased uptake, support steady revenue streams. However, price restrictions and generic competition threaten margin pressures moving forward.

What is the outlook for INVOKAMET XR’s financial trajectory?

Revenue Growth Forecast

Between 2023 and 2028, sales are projected to grow at an annual rate of roughly 4.5%, driven by expanding indications, increased awareness, and global adoption. Forecasted sales could reach $640 million in the U.S. and $1.2 billion globally.

Global Expansion

Markets outside the U.S., especially Europe, China, and India, present growth opportunities as diabetes management expands in emerging economies. Local regulatory approvals and pricing negotiations will influence growth rates.

Patent and Competition

The primary patent for INVOKAMET XR, expiring in late 2024, creates a risk of generics entering the market shortly thereafter, which could reduce revenue by approximately 40%, based on industry analogs.

Strategic Developments

Continued clinical trials exploring cardiovascular and renal outcomes will strengthen the drug's profile, potentially enabling expanded labeling and improved market positioning.

What risks could impact the financial trajectory?

• Patent expiration: Loss of exclusivity could significantly diminish revenue.
• Pricing pressures: Increased scrutiny from payers and regulators may limit price increases.
• Market penetration barriers: Regulatory delays or unfavorable reimbursement decisions could hinder expansion.
• Competitive developments: New drugs with superior efficacy or safety profiles may challenge INVOKAMET XR’s market share.

Key Takeaways

• INVOKAMET XR holds a stable position in the expanding type 2 diabetes market.
• Demand is driven by demographic trends, clinical guidelines, and its multifaceted benefits.
• Revenue growth is forecasted at around 4.5% annually through 2028, with significant risks from patent expiry and competition.
• Implementation in emerging markets offers new opportunities, contingent on local regulatory and pricing frameworks.
• Ongoing clinical data and trial results influence its long-term market position.

FAQs

Q1: When does the patent for INVOKAMET XR expire?
Patent protection is expected to expire in late 2024, opening the market to generics.

Q2: What are the main competitors to INVOKAMET XR?
Competitors include separate formulations like Janumet XR, Jardiance combinations, and emerging generic fixed-dose options.

Q3: How does insurance coverage impact sales?
Most payers include INVOKAMET XR in formulary tiers, facilitating reimbursement and patient access, essential for revenue stability.

Q4: Are there upcoming clinical trials influencing its market?
Yes, ongoing studies such as EMPA-KIDNEY aim to demonstrate renal benefits, potentially expanding indications.

Q5: What is the global market outlook?
Emerging markets display growth potential; however, their expansion depends on regulatory approvals and pricing negotiations.

---

References

[1] IDF. (2022). IDF Diabetes Atlas (10th ed.). International Diabetes Federation.
[2] IQVIA. (2023). Pharmaceutical Market Overview.
[3] GoodRx. (2023). Average wholesale prices, 2023.
[4] Zinman, B., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine, 373(22), 2117-2128.